Company to host corporate update webcast to
share results on December 11,
2024
LAUSANNE, Switzerland, Dec. 6, 2024
/PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today
announced that it will host a conference call and live webcast on
Wednesday, December 11, 2024, at
8:30 a.m. EST to provide an update on
preliminary data from the LOTIS-7
Phase 1b open-label clinical trial
evaluating the safety and efficacy of ZYNLONTA® in
combination with the bispecific antibody glofitamab
(COLUMVI™) in patients with relapsed or refractory
diffuse large B-cell lymphoma (r/r DLBCL).
To access the conference call, please register here. The
participant toll-free dial-in number is 1-800-836-8184 for
North America and Canada. It is recommended that you join 10
minutes before the event, though you may pre-register at any time.
A live webcast of the call will be available under "Events and
Presentations" in the Investors section of the ADC Therapeutics
website at ir.adctherapeutics.com. The archived webcast will be
available for 30 days following the call.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global
leader and pioneer in the field of antibody drug conjugates (ADCs).
The Company is advancing its proprietary ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in
London and New Jersey. For more information, please
visit https://adctherapeutics.com/ and follow the Company
on LinkedIn.
ZYNLONTA® is a registered trademark of ADC
Therapeutics SA.
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download
multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-provide-initial-data-update-on-lotis-7-clinical-trial-302324496.html
SOURCE ADC Therapeutics SA